Study of ARO-DIMERPA in Adult Participants With Mixed Hyperlipidemia

Study Summary

Study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD), and effects on low-density lipoprotein cholesterol (LDL-C) and triglycerides (TGs) of single-dose ARO-DIMERPA and multiple doses of ARO-DIMERPA in adult participants with mixed hyperlipidemia.

Conditions

Hyperlipidemia; Mixed

Interventions / Drugs

ARO-DIMERPA Placebo

View on ClinicalTrials.gov ↗

Sponsor

ARWR

Arrowhead Pharmaceuticals

RNAi Therapeutics

D36/100

Study Details

Enrollment78 participants

Primary Completion—

Lead SponsorArrowhead Pharmaceuticals

Data Retrieved2026-04-11 02:54:36.141212+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.